EyePoint Pharmaceuticals appoints new CMO

8 March 2024

USA-based ophthalmic diseases specialist EyePoint Pharmaceuticals (Nasdaq: EYPT) has appointed Ramiro Ribeiro as its new chief medical officer.

Dr Ribeiro, a trained retinal specialist, succeeds Dr Dario Paggiarino, who has held the position since 2016.

The appointment comes at a pivotal time for the company as it anticipates the Phase II PAVIA trial readout of its leading product candidate, EYP-1901, for non-proliferative diabetic retinopathy (NPDR) in the second quarter of this year. Additionally, EyePoint is preparing to initiate its first Phase III LUGANO pivotal trial for EYP-1901 in wet age-related macular degeneration (wet AMD in the second half of 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK